Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.34 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.33 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | NMT1 | P30419 | 1/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | CHKA | P35790 | 2/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1925545 | 0.99 | CNR2 (0.36) | CNR2NMT1TNKSENPP2HTR6 | |
| Hydrochloric Acid SCHEMBL1926043 | 0.93 | HTR6 (0.38) | NMT1HTR6IDO1TDO2IDO2 | |
| Hydrochloric Acid SCHEMBL1925370 | 0.92 | TNKS (0.37) | CNR2NMT1TNKSIDO1TDO2 | |
| SCHEMBL1926277 | 0.92 | HTR6 (0.38) | NMT1HTR6IDO1TDO2IDO2 | |
| SCHEMBL1924581 | 0.91 | TNKS (0.37) | CNR2NMT1TNKSIDO1TDO2 | |
| Hydrochloric Acid SCHEMBL1925700 | 0.91 | NMT1 (0.39) | CNR2NMT1GRIN1GRIN2BSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1925160 | 0.90 | CNR2 (0.42) | CNR2KCNH2 | |
| SCHEMBL1926302 | 0.90 | NMT1 (0.40) | CNR2NMT1GRIN1GRIN2BSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1926732 | 0.90 | KMT2A (0.41) | — | |
| Hydrochloric Acid SCHEMBL1926870 | 0.89 | LMNA (0.38) | CNR2NMT1TNKSIDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1431293-B1 | WATER-SOLUBLE PHENYLPYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME | KOWA CO (JP) | 2011-06-08 | — | — | EP | disclosed |
| US-7211577-B2 | Water-soluble phenylpyridazine derivative and medicine containing the same | KOWA CO., LTD. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-7087606-B2 | Water-soluble phenylpyridazine compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2006-08-08 | — | — | US | disclosed |
| US-20060142292-A1 | 4-(4-tert-butoxycarbonyl-1-piperazinyl)methyl-6-(3-fluoro-4-methylphenyl)-2-isobutyl-2H-pyridazin-3-one;inhibiting interleukin-1 beta, high water solubility and oral absorbability; treating immune system diseases, inflammatory diseases, and ischemic diseases | KOWA CO., LTD. (JP) | 2006-06-29 | — | — | US | disclosed |
| EP-1604984-A1 | WATER-SOLUBLE PHENYLPYRIDAZINE DERIVATIVE AND MEDICINE CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 2005-12-14 | — | — | EP | disclosed |
| US-20050085480-A1 | Water-soluble phenylpyridazine compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| US-6869954-B2 | Water-soluble phenylpyridazine compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2005-03-22 | — | — | US | disclosed |
| US-6861428-B2 | Water-soluble phenylpyridazine compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2005-03-01 | — | — | US | disclosed |
| EP-1431293-A1 | WATER-SOLUBLE PHENYLPYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
| US-20040002497-A1 | Water-soluble phenylpyridazine compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2004-01-01 | — | — | US | disclosed |
| US-20030119838-A1 | Water-soluble phenylpyridazine compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142292-A1 | 4-(4-tert-butoxycarbonyl-1-piperazinyl)methyl-6-(3-fluoro-4-methylphenyl)-2-isobutyl-2H-pyridazin-3-one;inhibiting interleukin-1 beta, high water solubility and oral absorbability; treating immune system diseases, inflammatory diseases, and ischemic diseases | IL1B, IL1A, IL1R1 | HTR6 2761/4885GRIN1 1555/4885GRIN2B 2939/4885 |
| US-20030119838-A1 | Water-soluble phenylpyridazine compounds and compositions containing the same | IL1A, IL1B, IL1R1 | HTR6 1885/4885GRIN1 519/4885GRIN2B 2978/4885 |
| US-20040002497-A1 | Water-soluble phenylpyridazine compounds and compositions containing the same | IL1A, IL1B, IL1R1 | HTR6 1563/4885GRIN1 591/4885GRIN2B 3083/4885 |
| US-20050085480-A1 | Water-soluble phenylpyridazine compounds and compositions containing the same | IL1A, IL1B, IL1R1 | HTR6 1603/4885GRIN1 484/4885GRIN2B 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.